Company intelligence / Profile preview

AGILeBiotics B.V.

Groningen, Groningen, Netherlandsagilebiotics.com ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

AGILeBiotics develops novel antibiotics using its proprietary OxaSelect platform to optimize existing antibiotic classes for activity against multidrug-resistant bacteria. The company’s approach aims to revive and improve the efficacy of established antibiotic scaffolds. No clinical results have been published as of the latest updates; programs are in preclinical development.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (novel antibiotics based on natural products)
Industry: Biotech

Drug pipeline

3 assets

ABX-265

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

University of Groningen academic groups led by Prof. Adriaan J. Minnaard and Prof. Andreas Herrmann support R&D activities at AGILeBiotics.

Beyond the preview

Go deeper on AGILeBiotics B.V..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGILeBiotics B.V..

Explore the full profile